Wells Fargo’s Avalo Therapeutics AVTX Stock Holding History

Wells Fargo’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$778K	Buy	+52,100	New	+$815K	﹤0.01%	3886

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wells Fargo's AVTX Position: Q4 2024 in Review

Wells Fargo sold out of Avalo Therapeutics (AVTX) in Q4 2024, closing a stake of 1 share — an estimated $10 sold.

Wells Fargo first reported a position in AVTX in Q2 2019 and held it in 21 quarters. The position peaked at $853K in Q2 2019. 33 funds tracked by Wall St. Rank hold AVTX as of Q4 2024.

Wells Fargo reported no remaining Avalo Therapeutics position as of Q4 2024 after selling out during the quarter.
Wells Fargo sold 1 Avalo Therapeutics share in Q4 2024, an estimated $10.
Wells Fargo first reported a position in Avalo Therapeutics in Q2 2019 and held it in 21 quarters.
Wells Fargo's Avalo Therapeutics position peaked at $853K in Q2 2019.
33 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2024.

Based on Wells Fargo's 13F filing for Q4 2024, filed 13 Feb 2025.